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Background: During rheumatoid arthritis (RA), steroids and biotherapies are used alone 
and combined. Efficacy has been established in clinical trials but their differential effects 
at the cellular level are less documented. The aim was to study these cellular effects 
using an in vitro model with synoviocytes interacting with peripheral blood mononuclear 
cells (PBMC) to reproduce the interactions in the RA synovium.
Methods: Activated-PBMC were cocultured with RA synoviocytes during 48 h. A dose–
response of methylprednisolone (MP) was tested and different biotherapies (Infliximab, 
Etanercept, Adalimumab, Tocilizumab, Abatacept, and Rituximab) were added alone or 
in combination with MP. Cytokine production (IL-17, IL-6, IL-1β, IFN-γ and IL-10) was 
measured by ELISA.
results: Addition of MP to cocultures inhibited the production of all cytokines. The 
response to the biotherapies alone was treatment-dependent. IL-17 production was 
inhibited only by Tocilizumab (p = 0.004), while IL-6 was decreased only by Infliximab 
(p ≤ 0.002). IL-1β level was affected in all conditions (p ≤ 0.03). IFN-γ production was 
mainly decreased by Infliximab (p =  0.004) and IL-10 by Infliximab and Tocilizumab 
(p ≤ 0.004). The combination MP and biotherapies did not induce an additional effect on 
pro-inflammatory cytokine inhibition. The combination MP and biotherapies induced a 
higher IL-10 secretion than MP alone, mainly with Rituximab.
conclusion: Steroids inhibited the secretion of all cytokines, and low doses were as 
potent. The anti-inflammatory effect of biotherapies was dependent on their mecha-
nism of action. MP and biotherapy combination did not enhance the inhibitory effect 
on  pro-inflammatory cytokines but could have a beneficial effect by increasing IL-10 
production.
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inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic inflammatory disease 
leading to joint destruction (1). Even if its etiology is not yet 
clarified, different treatments are available to treat the clinical 
symptoms. Steroids (also named glucocorticoids or corticos-
teroids) are the oldest and the most classical anti-inflammatory 
therapy used for many chronic inflammatory diseases other than 
RA. They act by inhibiting multiple inflammatory genes (encod-
ing cytokines, chemokines, etc.) that are activated during chronic 
inflammation (2–4). However, their use is associated with adverse 
events mainly infections specifically at high dose. Moreover, 
non-responsiveness or resistance can be observed (5). Another 
key drug is methotrexate (MTX), the most common treatment of 
RA. MTX improves clinical parameters in RA patients but severe 
adverse events could lead to discontinuation (6–8).
The heterogeneity of the response to steroids and MTX has 
led to a combination therapy with biotherapies. In RA, anti-TNF 
inhibitors are the first and most used biotherapy. Many studies 
have described the improvement of symptoms and physical func-
tions (9). Nevertheless, adverse events, mainly elevated risk of 
infections (10), are known and prevention measures are in place. 
Current studies focus on the clinical level of treatment efficacy, 
but the mode of action at the cellular level is less documented.
In the RA joint synovium, the inflammation leads to the recruit-
ment of immune cells that interact with local mesenchymal cells 
as synoviocytes. These interactions contribute to the chronicity 
of inflammation, notably by increasing the pro-inflammatory 
cytokine production and the cell survival of synoviocytes (11–13). 
In our previous studies, the effects of cell interactions on pro-
inflammatory cytokine production were studied using an in vitro 
model of coculture between mesenchymal cells and peripheral 
blood mononuclear cells (PBMC). These studies showed that cell 
interactions were critical for massive pro-inflammatory cytokine 
secretion. The use of an autologous system validated this model 
as mimicking the in vivo situation (14, 15).
Herein, in the RA inflammatory context, the aim was to com-
pare the effects of all the current biotherapies against TNF, IL-6, 
CD20, and CTLA4, with or without steroids by using this in vitro 
cell–cell interaction model looking at cytokine production.
MaTerials anD MeThODs
samples
Rheumatoid arthritis synoviocytes were obtained from synovial 
tissue of RA patients undergoing joint surgery and who fulfilled 
the American College of Rheumatology criteria for RA (16). 
Synovial tissue was minced into small pieces and then adhered 
in 6-well plates in Dulbecco’s modified Eagle’s medium (DMEM; 
Eurobio, Courtaboeuf, France), supplemented with 10% fetal 
bovine serum (FBS; Life Technologies, Carlsbad, USA), 2mM 
l-glutamine, and 100 U/ml penicillin/streptomycin. Cells were 
maintained at 37°C in a humidified 5% carbon dioxide incuba-
tor and used between passages 4 to 9. PBMC from healthy 
donors were isolated by Ficoll-Hypaque (Eurobio, Courtaboeuf, 
France) density-gradient centrifugation. Each individual signed 
an informed consent form. The protocol was approved by the 
Ethics Committee of the Hospitals of Lyon for the protection 
of persons participating in biomedical research under number 
AC-2010-11-64.
coculture assays
Coculture was initiated by seeding RA synoviocytes overnight 
in 96-well plates at a density of 2  ×  104 cells/well in RPMI 
1640 medium (Eurobio, Courtaboeuf, France) supplemented 
with 10% human AB serum, 2mM l-glutamine, and 100 U/ml 
penicillin/streptomycin (complete RPMI). The next day, healthy 
PBMC (1  ×  105 cells/well) were pre-incubated in complete 
RPMI with or without different treatments and then seeded 
corresponding to 5:1 ratio, in the presence of phytohemagglu-
tinin (PHA, 5 μg/ml). After 48 h, supernatants and PBMC were 
collected for analysis (17).
Treatments
A dose–response of Methylprednisolone (MP) was done with 0, 
0.001, 0.01, 0.1, 1, and 10 μg/ml. The concentration of 0.01 μg/ml 
was used in combination with biotherapies. Two concentrations of 
biotherapies were used in coculture, 10 and 100 μg/ml. Infliximab 
(Remicade, anti-TNF, Merk), Tocilizumab (Roactemra, anti-IL-6 
receptor, Roche-Chugai), Abatacept (Orencia, CTLA4 Ig, BMS), 
Rituximab (Mabthera, anti-CD20, Roche), Etanercept (Enbrel, 
anti-TNF, Amgen), and Adalimumab (Humira, anti-TNF, 
Abbvie) were tested.
enzyme-linked immunosorbent assays
IL-17A, IL-6, IL-1β, IFN-γ, and IL-10 production was evaluated 
from culture supernatants with commercially available Duoset 
enzyme-linked immunosorbent assays (ELISA) kits, according 
to the manufacturer’s instructions (R&D system, Minneapolis, 
MN, USA).
statistical analysis
Statistical analyses were performed using paired Wilcoxon test. 
All analyses were performed with Graph Pad Prism 6 software. 
p values less than or equal to 0.05 were considered as significant.
resUlTs
Principle of the In Vitro Model
During chronic inflammatory arthritis, immune cells infiltrate 
the inflammatory synovium and interact with local mesenchymal 
cells, as synoviocytes. This promotes the secretion of various 
cytokines and chemokines. To mimic this event, an in  vitro 
model of coculture was used. In the RA context, synoviocytes 
from patients were cultured in the presence of activated-PBMC. 
These cell–cell interactions lead to massive cytokine production, 
compared to PBMC alone. In control condition, the cell contact 
between synoviocytes and healthy resting-PBMC is sufficient to 
induce IL-6 and IL-1β production. Nevertheless, a high IL-17 
secretion is only obtained in coculture with activated-PBMC. 
This model was validated by using an autologous system, that is 
PBMC and synoviocytes from the same RA patients (14). Using 
FigUre 1 | Principle of the in vitro coculture model. Coculture between synoviocytes and activated-PBMC leads to cell interactions promoting the secretion of 
cytokines. Cell–cell contact induces IL-1β, TNF, or IL-10 production, mainly by monocytes. In turn, TNF and IL-1β stimulate synoviocytes to produce IL-6. Secreted 
cytokines influence T lymphocyte differentiation, as IL-6 and IL-1β for Th17 cells, and then interactions with synoviocytes promote the release of their cytokine, as 
IL-17 which, in turn, stimulates synoviocytes. The coculture reproduces the cell interactions existing in the inflammatory site and the cytokine environment. Using 
this model, the effect of treatments on cytokine production resulting from cell interactions can be studied.
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this model, the effect of treatments on cytokine production 
resulting from cell interactions could be studied (Figure 1).
effects of Methylprednisolone
The effect of MP was evaluated in the coculture system, using 
a dose–response curve. Different concentrations of MP were 
tested: 0, 0.001, 0.01, 0.1, 1, and 10 μg/ml. The impact on pro- 
and anti-inflammatory cytokine production was measured in the 
supernatants of cultures after 48 h. As observed in Figure 2, IL-17 
secretion was significantly decreased from 0.1 μg/ml (62.3 ± 24.7 
vs. 112.8  ±  33.8  pg/ml, p  =  0.03), but there was already a 
decreased production starting from 0.01  μg/ml (76.6  ±  27.8 
vs. 112.8 ±  33.8  pg/ml, p =  0.06). The inhibition followed a 
dose–response. IL-6, IL-1β, and IFN-γ production significantly 
decreased starting with the lowest concentration of 0.001  μg/
ml (234.7 ±  30.2 vs. 291.8 ±  20.2  ng/ml, for IL-6; 90.4 ±  31.7 
vs. 230.5 ± 77.8 pg/ml, for IL-1β, p = 0.008; 234.4 ± 136.5 vs. 
552.3 ± 217.6 pg/ml, for IFN-γ, p = 0.03). The dose effect was clear 
for IL-6 secretion and almost for IL-1β; nevertheless, for IFN-γ, 
the maximum effect was reached from the lowest concentration.
If MP inhibited well the production of pro-inflammatory 
cytokines, the secretion of the anti-inflammatory cytokine IL-10 
was also inhibited by the addition of MP. This decreased produc-
tion was significant from the lowest concentration of 0.001 μg/ml 
(32.0 ± 12.8 vs. 70.8 ± 23.6 pg/ml, p = 0.02) and was not clearly 
dose-dependent.
These results confirmed the anti-inflammatory potential of 
MP in in vitro system, but showed that MP also decreased the 
production of IL-10.
effects of Biotherapies alone
The effects of the current biotherapies for RA treatment were first 
tested alone. After preliminary experiments, two doses, 10 and 
100 μg/ml, were selected and tested for their effect on cytokine 
production. As shown in Figure 3, the effects of the addition of 
biotherapies in coculture were measured on the production of the 
pro-inflammatory cytokines IL-17, IL-6, IL-1β, and IFN-γ and 
the anti-inflammatory cytokine IL-10.
Infliximab is a monoclonal antibody that binds TNF. 
Infliximab decreased the production of IL-17 at 10  μg/ml, 
without reaching significance (78.5 ±  22.1 vs. 94.8 ±  26.1  pg/
ml, p = 0.07, Figure 3A) and also at 100 μg/ml (70.3 ± 24.3 vs. 
94.8 ± 26.1 pg/ml, p = 0.055, Figure 3A). On the other hand, IL-6 
production was decreased by around 30–35%, without a clear 
dose–response (223.7 ± 23.1 vs. 321.1 ± 30.1 ng/ml, for 10 μg/
ml, p = 0.001; 209.2 ± 27.5 vs. 321.1 ± 30.1 ng/ml, for 100 μg/
ml, p = 0.002, Figure 3A). The secretion of IL-1β and IFN-γ was 
the most inhibited by the addition of Infliximab, with a decrease 
around 60–70% (100.8 ± 28.1 vs. 250.7 ± 66.7 pg/ml, for 10 μg/ml 
and 74.5 ± 26.8 vs. 250.7 ± 66.7 pg/ml, for 100 μg/ml, for IL-1β, 
p = 0.002; 166.0 ± 67.9 vs. 532.0 ± 163.9 pg/ml, for 10 μg/ml and 
158.0 ± 55.9 vs. 532.0 ± 163.9 pg/ml, for 100 μg/ml, for IFN-γ, 
p = 0.004, Figure 3A). Furthermore, Infliximab also decreased by 
about 30% the production of IL-10 (46.3 ± 18.7 vs. 62.8 ± 17.5 pg/
ml, for 10 μg/ml, p = 0.05; 38.0 ± 16.2 vs. 62.8 ± 17.5 pg/ml, for 
100 μg/ml, p = 0.002, Figure 3A).
Tocilizumab is a monoclonal antibody that binds the IL-6 recep-
tor. Tocilizumab inhibited significantly the production of IL-17 
either at 10 μg/ml (62.0 ± 19.4 vs. 94.8 ± 26.1 pg/ml, p = 0.004, 
Figure 3B) or at 100 μg/ml (53.7 ± 16.7 vs. 94.8 ± 26.1 pg/ml, 
p = 0.004, Figure 3B), with a dose effect (p = 0.04, Figure 3B). 
While IL-1β production was also significantly decreased by the 
addition of Tocilizumab (106.5 ±  30.8 vs. 250.7 ±  66.7  pg/ml, 
for 10 μg/ml; 105.1 ± 30.4 vs. 250.7 ± 66.7 pg/ml, for 100 μg/ml, 
p = 0.002, Figure 3B), without a clear dose effect, the secretion of 
IL-6 was similar to the control (293.4 ± 33.1 vs. 321.1 ± 30.1 ng/
ml for 10 μg/ml; 293.3 ± 34.9 vs. 321.1 ± 30.1 ng/ml, for 100 μg/
FigUre 2 | effect of the dose–response of methylprednisolone on cytokine production. Healthy PBMC activated by PHA (5 μg/ml) were pre-incubated or 
not with different doses of methylprednisolone. Then, PBMC were cocultured with RA synoviocytes at a ratio 5:1 for 48 h. The production of IL-17, IL-6, IL-1β, 
IFN-γ, and IL-10 in cell supernatants was measured by enzyme-linked immunosorbent assay (ELISA). *p ≤ 0.05. Results are represented as mean ± SEM, n = 8 
experiments from six different RA patients.
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ml, Figure  3B). The IFN-γ secretion was significantly reduced 
with 10 μg/ml (340.1 ± 105.1 vs. 532.0 ± 163.9 pg/ml, p = 0.03, 
Figure  3B) but without reaching significance with 100  μg/ml 
(370.2 ±  137.0 vs. 532.0 ±  163.9  pg/ml, p =  0.09, Figure  3B), 
suggesting that high dose is not necessarily more efficient. The 
production of IL-10 was also significantly decreased by the addi-
tion of Tocilizumab (37.9 ± 12.6 vs. 62.8 ± 17.5 pg/ml, for 10 μg/
ml; 27.1 ± 9.2 vs. 62.8 ± 17.5 pg/ml, for 100 μg/ml, p = 0.002, 
Figure 3B).
Two biotherapies targeting specifically cells were also tested, 
Abatacept and Rituximab. Abatacept is a fusion protein (CTLA-
4-Ig) which interacts with B7 (ligand of CD28 which is a T cell 
activation molecule). The addition of Abatacept did not affect IL-17 
and IL-6 secretion at 10 μg/ml (96.1 ± 25.8 vs. 94.8 ± 26.1 pg/ml 
for IL-17; 309.5 ± 42.1 vs. 321.1 ± 30.1 ng/ml for IL-6, Figure 3C) 
and at 100 μg/ml (83.2 ± 24.5 vs. 94.8 ± 26.1 pg/ml for IL-17; 
291.9 ±  40.6 vs. 321.1 ±  30.1  ng/ml for IL-6, Figure  3C). The 
production of IL-1β was significantly decreased by about 45%, 
without a dose–effect (143.1 ± 40.4 vs. 250.7 ± 66.7 pg/ml, for 
10 μg/ml; 132.0 ±  40.5 vs. 250.7 ±  66.7  pg/ml, for 100 μg/ml, 
p =  0.002, Figure  3C). IFN-γ secretion was altered in a dose-
dependent pattern, as there was a significant decrease between 10 
and 100 μg/ml (356.6 ± 123.4 vs. 274.7 ± 95.2 pg/ml, respectively, 
p =  0.04, vs. 532.0 ±  163.9  pg/ml for the control, Figure  3C). 
IL-10 was decreased only with the higher dose of 100  μg/ml 
(48.9 ± 13.1 vs. 62.8 ± 17.5 pg/ml, p = 0.03, Figure 3C).
Rituximab is a monoclonal antibody against CD20. As 
observed in Figure 3D, Rituximab had no effect on the secretion 
of IL-17, IL-6, and IL-10. The concentration of 10 μg/ml decreased 
significantly IL-1β production (188.8 ± 60.6 vs. 250.7 ± 66.7 pg/
ml, p  =  0.04) and also IFN-γ secretion (370.2  ±  137.0 vs. 
532.0 ± 163.9 pg/ml, p = 0.02). At 100 μg/ml, their production 
was not significantly decreased and as for Tocilizumab, this 
suggests that increasing the dose may not be necessary and even 
could have an opposite effect.
In summary, a global inhibitory effect of all biotherapies was 
observed but with differences between treatments. Infliximab 
and Tocilizumab had a higher and broader effect than Abatacept 
and Rituximab. This could be explained by the broader effect 
of Infliximab and Tocilizumab acting on cytokines and their 
receptors contrasting with the cell specificity of Abatacept and 
Rituximab.
effects of Various anti-TnF comparisons
Various inhibitors of TNF are currently used with different modes 
of action. Infliximab was compared to two other TNF inhibitors, 
Etanercept, a soluble receptor, and Adalimumab, a monoclonal 
antibody like Infliximab. As observed in Figure  4, at both 
concentrations, only Adalimumab decreased significantly the 
secretion of IL-17 by about 30% (70.1 ± 24.0 vs. 99.2 ± 28.4 pg/
ml for 10 μg/ml; and 67.1 ± 22.0 vs. 99.2 ± 28.4 pg/ml for 100 μg/
ml, p = 0.008). The three biotherapies had a similar effect on IL-6 
FigUre 3 | effect of biotherapies on cytokine production. Healthy activated-PBMC were pre-incubated or not with two doses of biotherapies, 10 or 100 μg/ml 
and cocultured with RA synoviocytes at a ratio 5:1 for 48 h. Infliximab (a), Tocilizumab (B), Abatacept (c), and Rituximab (D) were tested. After 48 h, the production 
of IL-17, IL-6, IL-1β, IFN-γ, and IL-10 in cell supernatants was measured by ELISA. *p ≤ 0.05. Results are represented as mean ± SEM, n = 11 experiments from 
six different RA patients.
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and IFN-γ, with an inhibition by about 30 and 70%, respectively, 
with no clear dose effect (Figure 4). For IL-1β, Infliximab was 
the most potent at both concentrations of the three inhibitors 
(51.8 ±  15.8 vs. 230.3 ±  70.3 pg/ml for Infliximab, p =  0.004; 
133.0 ± 49.1 vs. 230.3 ± 70.3 pg/ml for Etanercept, p = 0.004; and 
138.4 ± 52.0 vs. 230.3 ± 70.3 pg/ml for Adalimumab, p = 0.004). 
The three anti-TNF inhibited significantly the IL-10 production, 
without a dose–effect. A difference between the three bio-
therapies was observed, significantly only at 10 μg/ml. Infliximab 
decreased less IL-10 production (47.0 ± 20.7 vs. 63.1 ± 19.3 pg/
ml for 10 μg/ml, p = 0.07; and 39.4 ± 17.9 vs. 63.1 ± 19.3 pg/ml 
for 100 μg/ml, p = 0.004), followed by Etanercept (31.2 ± 14.5 
vs. 63.1 ±  19.3 pg/ml for 10 μg/ml, p =  0.03; and 25.8 ±  15.5 
vs. 63.1 ± 19.3 pg/ml for 100 μg/ml, p = 0.008); and the most 
inhibitory effect was obtained with Adalimumab (18.7 ± 9.0 vs. 
63.1 ±  19.3 pg/ml for 10 μg/ml, p =  0.004; and 18.9 ±  9.9 vs. 
63.1 ± 19.3 pg/ml for 100 μg/ml, p = 0.004). Overall, the three 
anti-TNF displayed a similar effect. Nevertheless, Infliximab was 
the more potent on IL-1β inhibition and less than the others on 
IL-10 secretion.
combination of MP and Biotherapies
The effect of treatment combination is not well understood in 
patients, and thus the basis for combining drugs remains unclear. 
The effect of MP and biotherapies, alone or in combination, was 
compared. The lowest effective doses of MP, 0.01 μg/ml and of 
biotherapies, 10  μg/ml, were used alone or in combination to 
evaluate their impact on cytokine production. MP alone inhibited 
significantly IL-17 production (58.9 ±  23.4 vs. 94.8 ±  26.1 pg/
ml, p =  0.02, Figure  5A) as Tocilizumab alone (62.0  ±  19.4 
vs. 94.8  ±  26.1  pg/ml, p  =  0.004, Figure  5A). Infliximab, 
Abatacept, and Rituximab alone did not inhibit IL-17 produc-
tion (Figure 5A). In combination, the inhibitory effect of MP and 
Tocilizumab was not increased and the inhibition was still around 
40% (56.5 ± 20.6 vs. 94.8 ± 26.1 pg/ml, p = 0.004, Figure 5A). 
The combination of MP and Infliximab or Abatacept tended to 
increase IL-17 production compared to MP alone (73.3 ± 20.8 and 
85.7 ± 27.8 pg/ml, respectively, vs. 58.9 ± 23.4 pg/ml, p = 0.07, 
Figure 5A). The combination of MP and Rituximab significantly 
inhibited the MP effect and the level of IL-17 was similar to the 
control (102.3 ± 30.6 vs. 94.8 ± 26.1 pg/ml, p = 0.03, Figure 5A).
FigUre 5 | effect of the combination of methylprednisolone and biotherapy on pro-inflammatory cytokine production. Healthy activated-PBMC were 
pre-incubated or not with methylprednisolone alone (0.01 μg/ml), biotherapy alone (10 μg/ml), or with the combination of both treatments. Then, PBMC were 
cocultured with RA synoviocytes at a ratio 5:1 for 48 h. Infliximab (a), Tocilizumab (B), Abatacept, (c) and Rituximab (D) were tested. After 48 h, the production of 
IL-17, IL-6, IL-1β, and IFN-γ in cell supernatants was measured by ELISA. *,#p ≤ 0.05. *Compares with control and #compares combination MP/biotherapy vs. MP 
alone. Results are represented as mean ± SEM, n = 11 experiments from six different RA patients.
FigUre 4 | comparison of different anti-TnF biotherapies. Healthy activated-PBMC were pre-incubated or not with two doses of anti-TNF biotherapies, 
10 μg/ml or 100 μg/ml and cocultured with RA synoviocytes at a ratio 5:1 for 48 h. Infliximab, Etanercept, and Adalimumab were compared. After 48 h, the 
production of IL-17, IL-6, IL-1β, IFN-γ, and IL-10 in cell supernatants was measured by ELISA. *,#p ≤ 0.05. *Compares anti-TNF vs. control and #compares the 
different anti-TNF. Results are represented as mean ± SEM, n = 10 experiments from six different RA patients.
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For IL-6 secretion, MP and Infliximab alone decreased signifi-
cantly IL-6 secretion compared to control (167.7 ± 21.0 pg/ml and 
78.5 ± 22.1 pg/ml, respectively, vs. 321.1 ± 30.1 pg/ml, p = 0.001, 
Figure 5B); and the combination of both increased significantly 
the inhibitory effect compared to MP alone (131.3 ±  13.6 vs. 
167.7 ± 21.0 pg/ml, p = 0.04, Figure 5B). The combination of MP 
FigUre 6 | effect of the combination of methylprednisolone and biotherapy on il-10 production. Healthy activated-PBMC were pre-incubated or not with 
methylprednisolone alone (0.01 μg/ml), biotherapy alone (10 μg/ml), or with the combination of both treatments. Then, PBMC were cocultured with RA synoviocytes 
at a ratio of 5:1 for 48 h. Infliximab, Tocilizumab, Abatacept, and Rituximab were tested. After 48 h, the production of IL-10 in cell supernatants was measured by 
ELISA. *p ≤ 0.05. *Compares with control. Results are represented as mean ± SEM, n = 10 experiments from six different RA patients.
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with other biotherapies (Tocilizumab, Abatacept, and Rituximab) 
did not change the decreased IL-6 production induced by MP 
alone (Figure 5B).
IL-1β production was decreased in a similar way between 
MP alone, Infliximab, Tocilizumab, or Abatacept alone and 
the combination of both (Figure 5C). Nevertheless, Rituximab 
alone inhibited IL-1β secretion but to a less extent that MP 
alone, compared to control (188.8 ± 60.6 pg/ml, p = 0.04, and 
104.5 ± 59.2 pg/ml, p = 0.002, respectively, vs. 250.7 ± 77.8 pg/
ml); and the combination of both canceled the large inhibitory 
effect of MP alone (218.4 ± 70.4 vs. 104.5 ± 59.2 pg/ml, p = 0.03, 
Figure 5C).
Except Abatacept, biotherapies (Infliximab, Tocilizumab and 
Rituximab) or MP alone decreased significantly the production 
of IFN-γ compared to control (Figure  5D). The combina-
tion of MP and Infliximab led to a similar inhibition than MP 
alone (252.2  ±  110.6 vs. 254.2  ±  169.2  pg/ml compared to 
532.0 ± 163.9 pg/ml for control, Figure 5D). The combination 
of MP with Tocilizumab and Rituximab significantly reduced 
the inhibition of IFN-γ secretion compared to MP alone 
(389.3 ± 159.4 pg/ml, p = 0.03, and 415.1 ± 178.1 pg/ml, p = 0.01, 
respectively, vs. 254.2 ±  169.2  pg/ml, Figure  5D), and it was 
the same tendency for the combination of MP and Abatacept 
(p = 0.08, Figure 5D).
Herein, the results showed that the combination even at low 
doses did not necessarily result in an additional effect on the 
inhibition of pro-inflammatory cytokine production.
effect on il-10 secretion
Given some unexpected results on pro-inflammatory cytokines 
with the combination of MP and biotherapy, the next step was 
to detect a potential effect on the anti-inflammatory cytokine 
IL-10. The dose of 0.01 μg/ml of MP alone decreased IL-10 pro-
duction compared to control (28.0 ± 9.1 vs. 62.8 ± 17.5 pg/ml, 
p = 0.01, Figure 6). Infliximab and Tocilizumab alone inhibited 
significantly the IL-10 secretion (46.3 ± 18.7 pg/ml, p = 0.05, and 
37.9 ± 12.6 pg/ml, p = 0.002, respectively, vs. 62.8 ± 17.5 pg/ml, 
Figure 6), while Abatacept and Rituximab did not affect the IL-10 
level compared to control (63.8 ± 23.7 pg/ml and 61.6 ± 21.2 pg/
ml, respectively, vs. 62.8 ± 17.5 pg/ml, Figure 6). In the presence of 
the combination of MP and biotherapy, the IL-10 level was lower 
than control but higher than MP alone, mainly with Rituximab, 
without reaching significance (48.1 ± 16.3 vs. 28.0 ± 9.1 pg/ml, 
p = 0.3, Figure 6). These results indicated that the beneficial effect 
of combination of MP and biotherapy could come from a reduc-
tion of the inhibitory effect of MP on IL-10 production.
DiscUssiOn
In this study, the interest was focused on the effects of steroids 
and biotherapies alone and combined on cytokine production 
resulting from cell interactions between mesenchymal cells and 
immune cells.
Steroids are very effective anti-inflammatory drugs but the 
adverse effects limit their use. There is no doubt that steroids 
present a strong potential for frequent and serious side effects, 
increasing with longer use and higher dose (18). Side effects of 
chronic steroid therapy are dose-related. At a low-dose (<7.5 mg/
day), many studies suggest that steroid treatment is relatively safe 
in RA (19, 20), and even a very low dose (<5  mg/ml), can be 
sufficient to maintain remission without severe adverse events 
(21) but a better clinical response (22–25). To identify their 
effects at the cellular level, an in vitro model based on interactions 
between mesenchymal cells and PBMC was used to mimic the 
in vivo inflammatory state. A dose–response with MP was done 
to evaluate its effects on cytokine production. The production of 
pro-inflammatory cytokines was clearly inhibited by the addition 
of MP in coculture with differences between cytokines. If IL-17 
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and IL-6 production decreased according to a dose–response, 
IL-1β and IFN-γ secretion was already inhibited with the lowest 
concentration of 0.001 μg/ml. A low dose of MP appears sufficient 
to induce an inhibitory effect on pro-inflammatory cytokine pro-
duction. Furthermore, from 10 μg/ml the cytokine production, 
notably IL-6 and IL-1β, appeared to increase compared to 1 μg/
ml. In the clinic, this would suggest high dosage of MP might 
not be needed to obtain its anti-inflammatory effect through 
cytokine inhibition and that high doses could have the opposite 
effect. In addition, the presence of MP even at the lowest dose also 
inhibited the secretion of IL-10. This may explain the increased 
risk of infection for the treated patients.
The use of biotherapies during chronic inflammatory diseases, 
such as RA, has been a major step in improved care. The benefits 
on clinical symptoms are well established, while the effect at cel-
lular levels is less documented. Our in vitro system demonstrated 
in previous studies that cell interactions between mesenchymal 
cells including synoviocytes from RA patients or skin fibroblasts 
from psoriatic patients and immune cells resulted in massive 
pro-inflammatory cytokine production as observed in the in vivo 
situation (14, 15). Our system was used to evaluate the effect of 
current biotherapies at the cytokine production level.
TNF is a pro-inflammatory cytokine clearly involved in the 
pathogenesis of RA (1, 26), notably by stimulating synoviocytes 
to produce IL-6. As expected, TNF inhibition led to a decreased 
production of IL-6 which is also a pro-inflammatory cytokine 
involved in the activation of T cell differentiation. The decrease 
of IL-6 level could result in the decreased IL-1β and IFN-γ 
levels. The most used anti-TNF treatments are Infliximab, 
Etanercept, and Adalimumab, and some studies showed differ-
ences in efficacy and adherence between them (27, 28). When 
compared at the cellular level, the three therapies displayed a 
rather similar inhibitory effect on pro-inflammatory cytokine 
production. The major difference appeared on IL-10 produc-
tion, with Infliximab inhibiting less IL-10 production compared 
to the two others.
Two-thirds of the RA patients respond to anti-TNF leav-
ing space for other treatment options (27). Tocilizumab is a 
recombinant humanized monoclonal antibody against the IL-6 
receptor (IL-6R), preventing IL-6 binding to both membranous 
and soluble IL-6R (29, 30). In our in vitro system, Tocilizumab 
decreased significantly IL-1β and IL-17 secretion (26, 31, 32). 
Both IL-6 and IL-1β are involved in the Th17 differentiation. Thus, 
the inhibition of IL-6R followed by the decrease of IL-1β could 
explain the observed inhibition of IL-17 secretion. The secretion 
of IL-6 was not decreased by the addition of Tocilizumab but such 
detection is complex. Indeed, in RA patients, the serum level of 
IL-6 increases after Tocilizumab administration, as IL-6 does not 
bind its receptor (33). Nevertheless, its signaling pathway is well 
inhibited as confirmed by the decreased production of CRP in 
patients.
In addition to cytokine inhibition, other biotherapies target 
cells. In this way, two other biotherapies, Abatacept and Rituximab 
were tested on cytokine production. Abatacept is a fusion protein 
of the extracellular domain of cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and the Fc region of IgG1. It prevents T cell 
activation by CD28 by increasing the inhibitory effect of CTLA-4 
on T cell activation (34). In our in vitro system, the major inhib-
ited cytokine was IL-1β. The decrease of IFN-γ production could 
be explained by the direct effect of Abatacept on T cell activation. 
In addition, IL-1β is involved in IFN-γ secretion by T cells (35, 
36) and NK cells (37). Thus, Abatacept may have a direct effect 
on T cell activation and an indirect effect by inhibiting IL-1β 
production.
Rituximab is directed against CD20 and induces the death of 
B cells (38). Herein, Rituximab decreased only IL-1β and IFN-γ 
production, at low dose. As Rituximab acts directly on B cells, it 
could be interesting to study the in vitro effect on immunoglobu-
lin production. Indeed, patients positive for anti-citrullinated 
protein antibodies (ACPA) appear to respond better to Rituximab 
(39–41).
Steroids and biotherapies are two different ways to diminish 
inflammation, by reducing cytokine production. The first conclu-
sion is that high doses were not more efficient than low doses, for 
both steroids and biotherapies. The effect of their combination 
each at low dose is more complex. Addition of a biotherapy 
seemed to reduce the effect of MP alone. At the same time, the 
combination reduced the inhibitory effect on IL-10 production 
of the two treatments used alone. At the end, the combination 
may increase the net anti-inflammatory effects of IL-10 with a 
suppressor effect on numerous pro-inflammatory cytokines, such 
as TNF, IL-1β, or IL-6, all involved in RA pathogenesis. The next 
step of these studies will be to evaluate this time the effects of 
MTX alone and combined with biotherapies, as done routinely 
in patients with RA and other inflammatory diseases.
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